Ciprofloxacin

Pharmacologic Category

Antibiotic, Fluoroquinolone

Dosing: Adult

Note: Extended-release tablets and immediate-release formulations are not interchangeable. Unless otherwise specified, oral dosing reflects the use of immediate-release formulations.

Anthrax: Note: Consult public health officials for event-specific recommendations.

Inhalational exposure (postexposure prophylaxis):

Oral: 500 mg every 12 hours for 60 days

IV: 400 mg every 12 hours for 60 days

Note: Anthrax vaccine should also be administered to exposed individuals (CDC [Hendricks 2014]).

Cutaneous (without systemic involvement), treatment (off-label use): Oral: 500 mg every 12 hours for 7 to 10 days after naturally acquired infection; 60 days following biological weapon-related event. Note: Patients with cutaneous lesions of the head or neck or extensive edema should be treated for systemic involvement (CDC [Hendricks 2014]).

Systemic (meningitis excluded), treatment (off-label use): IV: 400 mg every 8 hours, in combination with other appropriate agents for 2 weeks or until clinically stable, whichever is longer (CDC [Hendricks 2014])

Meningitis, treatment (off-label use): IV: 400 mg every 8 hours, in combination with other appropriate agents for 2 to 3 weeks or until clinically stable, whichever is longer (CDC [Hendricks 2014])

Note: Antitoxin should also be administered for systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (CDC [Hendricks 2014]).

Bite wound infection, prophylaxis or treatment (animal and human bites) (alternative agent) (off-label use): Note: Use in combination with an appropriate agent for anaerobes.

Oral: 500 to 750 mg twice daily

IV: 400 mg every 12 hours

Duration of therapy: 3 to 5 days for prophylaxis (IDSA [Stevens 2014]); duration of treatment for established infection is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (Baddour 2019a; Baddour 2019b).

Cat scratch disease, lymphadenitis (nondisseminated) (alternative agent) (off-label use): Oral: 500 mg twice daily (Holley 1991).

Chancroid (alternative agent) (off-label use): Oral: 500 mg twice daily for 3 days (CDC [Workowski 2015])

Cholera (Vibrio cholerae) (alternative agent) (off-label use): Oral: 1 g as a single dose (IDSA [Guerrant 2001]; Khan 1996)

Chronic obstructive pulmonary disease, acute exacerbation (off-label use): Note: Some experts reserve for patients with risk factors for poor outcomes (eg, ≥65 years of age, FEV1 <50% predicted, frequent exacerbations, significant comorbidities) who are at risk of Pseudomonas infection (Sethi 2020).

Oral: 500 to 750 mg twice daily (Nouira 2010; Umut 1999) for 3 to 7 days (GOLD 2020; Sethi 2020).

Crohn disease, treatment of simple perianal fistulas (off-label use): Oral: 500 mg twice daily, with or without metronidazole, for 4 weeks (ACG [Lichtenstein 2018]; Bitton 2019); some experts recommend treatment duration up to 8 weeks (ACG [Lichtenstein 2018]).

Diabetic foot infection (off-label use): Note: When used as empiric therapy, ciprofloxacin should be used in combination with other appropriate agents.

Mild to moderate infection: Oral: 500 mg every 12 hours (750 mg every 12 hours if Pseudomonas aeruginosa is suspected) (IDSA [Lipsky 2012]; Weintrob 2019).

Moderate to severe infection: IV: 400 mg every 12 hours (400 mg every 8 hours if P. aeruginosa is suspected) (IDSA [Lipsky 2012]; Weintrob 2019).

Endocarditis due to HACEK organisms (alternative agent) (off-label use):

Oral: 500 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve) (AHA [Baddour 2015]).

IV: 400 mg every 12 hours for 4 weeks (native valve) or 6 weeks (prosthetic valve) (AHA [Baddour 2015]).

Granuloma inguinale (donovanosis) (alternative agent) (off-label use): Oral: 750 mg twice daily for ≥3 weeks (and until lesions have healed). Note: If symptoms do not improve within the first few days of therapy, another agent (eg, aminoglycoside) can be added (CDC [Workowski 2015]).

Intra-abdominal infection (including perforated appendix, appendiceal abscess, acute diverticulitis, acute cholecystitis), community-acquired: Note: For empiric therapy, usually administered in combination with metronidazole. The addition of metronidazole may not be necessary for uncomplicated biliary infection of mild to moderate severity (SIS/IDSA [Solomkin 2010]; Vollmer 2019). Empiric oral regimens may be appropriate for patients with mild to moderate infection. Other patients may be switched from IV to oral therapy when clinically improved and able to tolerate an oral diet (SIS [Mazuski 2017]; SIS/IDSA [Solomkin 2010]).

Oral: 500 mg every 12 hours

IV: 400 mg every 12 hours

Duration: Duration of therapy is for 4 to 7 days following adequate source control (SIS/IDSA [Solomkin 2010]); for uncomplicated appendicitis and diverticulitis managed nonoperatively, a longer duration is necessary (Barshak 2019; Pemberton 2019).

Meningitis, bacterial (community-acquired or health care-associated) (alternative agent) (off-label use): IV: 400 mg every 8 to 12 hours; for empiric therapy, must be used in combination with other appropriate agents (IDSA [Tunkel 2004]; IDSA [Tunkel 2017])

Meningococcal meningitis prophylaxis (off-label use): Oral: 500 mg as a single dose (CDC 2005)

Neutropenia (chemotherapy-induced), antibacterial prophylaxis in high-risk patients anticipated to have an ANC ≤100 cells/mm3 for >7 days (off-label use): Oral: 500 to 750 mg twice daily (IDSA [Freifeld 2011]; Wingard 2019); some clinicians will provide antibacterial prophylaxis if ANC is anticipated to be <500 cells/mm3 for >7 days (Wingard 2019). For hematopoietic cell transplant recipients, begin at the time of stem cell infusion and continue until recovery of neutropenia or until initiation of empiric antibiotic therapy for neutropenic fever (Tomblyn 2009).

Neutropenic fever, low-risk cancer patients (empiric therapy) (off-label use): Oral: 750 mg every 12 hours (Kern 1999; Kern 2013) in combination with amoxicillin and clavulanate; continue until fever and neutropenia have resolved. Note: Avoid in patients who have received fluoroquinolone prophylaxis. Administer first dose in the health care setting (after blood cultures are drawn); observe patient for ≥4 hours before discharge (ASCO/IDSA [Taplitz 2018]; IDSA [Freifeld 2011]).

Osteomyelitis:

Oral:

Treatment: 500 to 750 mg every 12 hours; when treating P. aeruginosa, 750 mg every 12 hours for ≥6 weeks (Calhoun 2005; IDSA [Berbari 2015]; Osmon 2019).

Chronic suppression in presence of retained infected orthopedic hardware: 250 to 500 mg every 12 hours (IDSA [Osmon 2013]).

IV: 400 mg every 12 hours; when treating P. aeruginosa, 400 mg every 8 hours for ≥6 weeks (Calhoun 2005; IDSA [Berbari 2015]; Osmon 2019).

Peritoneal dialysis catheter, exit-site or tunnel infection (off-label use): Oral: 250 mg twice daily. When used for empiric therapy, must be used in combination with other appropriate agents (ISPD [Szeto 2017]).

Peritonitis, spontaneous bacterial (prevention), high-risk patients (eg, hospitalized patients with Child-Pugh class B or C cirrhosis and active GI bleeding) (alternative agent) (off-label use):

Oral: 500 mg every 12 hours; total duration of therapy is 7 days (parenteral and oral) (Runyon 2019).

IV (alternative for nonfunctional GI tract): 400 mg every 12 hours; total duration of therapy is 7 days (parenteral and oral) (Runyon 2019).

Long-term secondary spontaneous bacterial peritonitis prophylaxis: Oral: 500 mg once daily (Runyon 2019).

Plague (Yersinia pestis) infection (alternative agent): Note: Consult public health officials for event-specific recommendations:

Postexposure prophylaxis: Oral: 500 mg twice daily for 7 days (CDC 2015a).

Treatment: Note: Duration of therapy is 10 to 14 days (CDC 2015a).

Oral: 500 to 750 mg every 12 hours (CDC 2015a).

IV: 400 mg every 8 to 12 hours (CDC 2015a).

Pneumonia, as a component of empiric therapy or pathogen-specific therapy for P. aeruginosa in hospitalized patients: Note: For empiric therapy, must be used in combination with other appropriate agents.

Oral: 750 mg every 12 hours (File 2019; IDSA [Kalil 2016]; Klompas 2019).

IV: 400 mg every 8 hours (File 2019; IDSA [Kalil 2016]; Klompas 2019).

Duration of therapy: 7 days; may be individualized based on patient-specific factors and response to therapy (IDSA [Kalil 2016]; Klompas 2019).

Prostatitis:

Acute bacterial prostatitis (off-label use):

Oral: 500 mg every 12 hours (Meyrier 2019a).

IV: 400 mg every 12 hours (Meyrier 2019a).

Duration of therapy: 4 to 6 weeks (Meyrier 2019a; Yoon 2013).

Chronic bacterial prostatitis: Oral: 500 mg every 12 hours for 4 to 6 weeks (Meyrier 2019b).

Prosthetic joint infection (off-label use): Note: Alternative agent for certain pathogens.

Treatment:

Gram-negative bacilli:

Oral: 750 mg twice daily (IDSA [Osmon 2013]).

IV: 400 mg every 12 hours (IDSA [Osmon 2013]); some experts prefer 400 mg every 8 hours for infections caused by P. aeruginosa (Berbari 2019).

Staphylococcus aureus, oral continuation therapy (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis):

Oral: 500 to 750 mg twice daily (Berdal 2005; Zimmerli 1998) in combination with rifampin; total treatment duration is a minimum of 3 months, depending on patient-specific factors (Berbari 2019; IDSA [Osmon 2013]).

Chronic suppressive therapy for P. aeruginosa: Oral: 250 to 500 mg twice daily (IDSA [Osmon 2013]).

Salmonella species, GI infection:

Nontyphoidal, severe (nonbacteremic) illness or any severity in patients at high risk for invasive disease: Oral: 500 mg twice daily for 3 to 7 days. Note: Immunosuppressed patients require longer duration of treatment (eg, weeks to months) (Hohmann 2019; IDSA [Guerrant 2001]).

Typhoid fever (Salmonella typhi and paratyphi): Severe disease or mild to moderate infection in patients at high risk of developing invasive disease (Ryan 2019)

Oral: 500 mg every 12 hours for 7 to 10 days.

IV: 400 mg every 12 hours for 7 to 10 days.

Septic arthritis (without prosthetic material) (alternative agent): Note: Use in combination with an aminoglycoside for initial treatment if P. aeruginosa suspected (Goldenberg 2019).

Oral: 500 to 750 mg twice daily.

IV: 400 mg every 12 hours.

Duration of therapy: 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (Goldenberg 2019).

Shigella GI infection (off-label dose): Oral: 500 mg twice daily or 750 mg once daily for 3 days; the duration should be extended to 5 to 7 days for those with Shigella dysenteriae type 1 infection or HIV coinfection (Agha 2019; IDSA [Guerrant 2001]).

Surgical (preoperative) prophylaxis (alternative agent) (off-label use): Note: Use in combination with other appropriate agents may be warranted (procedure-dependent). IV: 400 mg within 120 minutes prior to surgical incision (Bratzler 2013).

Surgical site infection (intestinal or GU tract, perineum, or axilla) (off-label use):

Oral: 750 mg every 12 hours, in combination with metronidazole (IDSA [Stevens 2014]).

IV: 400 mg every 12 hours, in combination with metronidazole (IDSA [Stevens 2014]).

Traveler's diarrhea, uncomplicated (empiric therapy) (off-label dose): Oral: 500 mg twice daily for 3 days or 750 mg as a single dose (ACG [Riddle 2016]; Riddle 2017). If symptoms not resolved after 24 hours following single-dose therapy, continue with 500 mg twice daily for 2 more days. The 3-day therapy course is recommended in patients with fever or dysentery; enteric infection due to S. dysenteriae is an exception as a 5-day treatment duration appears to be superior to single-dose or 3-day regimens (ACG [Riddle 2016]). Note: Fluoroquinolone resistance is increasing; azithromycin may be preferred, particularly in regions such as Southeast Asia or India with a high prevalence of Campylobacter (ACG [Riddle 2016]).

Tularemia (Francisella tularensis) (off-label use): Note: Consult public health officials for event-specific recommendations.

Mild disease: Oral: 500 or 750 mg twice daily for 10 to 14 days (Bossi 2004; Dennis 2001).

Postexposure prophylaxis: Oral: 500 or 750 mg twice daily for 14 days (Bossi 2004; Dennis 2001).

Urinary tract infection: Note: Uncomplicated urinary tract infection (UTI) has traditionally been defined as infection in an otherwise healthy nonpregnant female with a normal urinary tract; UTI in other patient populations has been considered complicated. Some experts instead categorize UTI as either acute simple cystitis (mild infection limited to the bladder with no signs/symptoms of upper tract or systemic infection in a nonpregnant adult) or complicated UTI (pyelonephritis or cystitis symptoms with other signs/symptoms of systemic infection) (Hooton 2019a; Hooton 2019b).

Acute uncomplicated or simple cystitis in females: Note: Use is discouraged due to safety concerns and significant Escherichia coli resistance; reserve for those who have no alternative treatment options (Bidell 2016; FDA Drug Safety Communication 2016; Hooton 2019a; IDSA [Gupta 2011]).

Oral, immediate release: 250 mg every 12 hours for 3 days.

Oral, extended release: 500 mg every 24 hours for 3 days.

Acute pyelonephritis or other complicated UTI: Note: If the prevalence of fluoroquinolone resistance is >10%, an initial dose of a long-acting parenteral antimicrobial, such as ceftriaxone, ertapenem, or a consolidated 24-hour dose of an aminoglycoside is recommended for outpatients (Hooton 2019b; IDSA [Gupta 2011]).

Oral, immediate release: 500 mg every 12 hours for 5 to 7 days.

Oral, extended release: 1,000 mg every 24 hours for 5 to 7 days.

IV (inpatient): 400 mg every 12 hours for a total of 5 to 7 days.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

Manufacturer's labeling:

Oral, immediate release:

CrCl >50 mL/minute: No dosage adjustment necessary.

CrCl 30 to 50 mL/minute: 250 to 500 mg every 12 hours

CrCl 5 to 29 mL/minute: 250 to 500 mg every 18 hours

ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 250 to 500 mg every 24 hours

Oral, extended release:

CrCl >30 mL/minute: No dosage adjustment necessary.

CrCl ≤30 mL/minute:

Cystitis, acute uncomplicated: No dosage adjustment necessary.

UTI, complicated (including pyelonephritis): 500 mg every 24 hours

ESRD on intermittent hemodialysis (IHD)/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours

IV:

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl 5 to 29 mL/minute: 200 to 400 mg every 18 to 24 hours

Alternative recommendations: Oral (immediate release), IV:

CrCl >50 mL/minute: No dosage adjustment necessary (Aronoff 2007).

CrCl 10 to 50 mL/minute: Administer 50% to 75% of usual dose every 12 hours (Aronoff 2007).

CrCl <10 mL/minute: Administer 50% of usual dose every 12 hours (Aronoff 2007).

Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Minimally dialyzable (<10%): Oral: 250 to 500 mg every 24 hours or IV: 200 to 400 mg every 24 hours (Heintz 2009). Note: Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.

Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:

CVVH/CVVHD/CVVHDF: IV: 200 to 400 mg every 12 to 24 hours

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in manufacturer's labeling. Use with caution in severe impairment.

Dosing: Pediatric

Note: In pediatric patients, ciprofloxacin is not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for some situations [eg, anthrax, resistance (cystic fibrosis)] or in situations where the only alternative is parenteral therapy and ciprofloxacin offers an oral therapy option (Bradley 2011b). Oral liquid products are available in two concentrations (ie, 50 mg/mL and 100 mg/mL); precautions should be taken to verify product selection and avoid confusion between the different concentrations. Extended release tablets and immediate release formulations are not interchangeable.

General dosing, susceptible infection (Red Book [AAP 2015]): Infants, Children, and Adolescents:

Mild to moderate infections: Oral, immediate release: 10 mg/kg/dose twice daily; maximum dose: 500 mg/dose

Severe infections:

Oral, immediate release: 15 to 20 mg/kg/dose twice daily; maximum dose: 750 mg/dose

IV: 10 mg/kg/dose every 8 to 12 hours; maximum dose: 400 mg/dose

Anthrax: Infants, Children, and Adolescents:

Cutaneous, without systemic involvement: AAP recommendations: Oral, immediate release: 15 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose. Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event (AAP [Bradley 2014])

Inhalational (postexposure prophylaxis):

Oral, immediate release: 15 mg/kg/dose every 12 hours for 60 days; maximum dose: 500 mg/dose

IV: 10 mg/kg/dose every 12 hours for 60 days; maximum dose: 400 mg/dose; may substitute oral antibiotics for IV antibiotics as soon as clinical condition improves

Systemic (including meningitis): AAP recommendations (Bradley 2014):

Initial treatment as part of combination therapy: IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose; continue until clinical criteria for stability are met

Oral step-down to complete a 60 day total course: Oral, immediate release: 15 mg/kg/dose twice daily

Campylobacteriosis, HIV-exposed/-infected (HHS [adult] 2015): Duration of therapy: 7 to 10 days for gastroenteritis, at least 14 days for bacteremia, 2 to 6 weeks for recurrent bacteremic disease

Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours

IV: Adolescents: 400 mg every 12 hours

Catheter (peritoneal dialysis); exit-site or tunnel infection: Infant, Children, and Adolescents: Oral, immediate release: 10 to 15 mg/kg/dose once daily; maximum dose: 500 mg/dose (Warady [ISPD 2012])

Chancroid: Adolescents: Oral, immediate release: 500 mg twice daily for 3 days (Red Book [AAP 2015])

Cystic fibrosis: Limited data available: Children and Adolescents:

Oral, immediate release: 20 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose (Stockmann 2012)

IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose (Stockmann 2012)

Endocarditis, culture negative, empiric therapy: AHA guidelines (Baltimore 2015): Administer in combination with other antibiotics: Children and Adolescents:

Oral, immediate release: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 750 mg/dose

IV: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 400 mg/dose

Infectious diarrhea: Limited data available:

Cholera: Infants, Children, and Adolescents: Oral, immediate release: 15 mg/kg/dose twice daily for 3 days; maximum dose: 500 mg/dose (Red Book [AAP 2015]; WHO 2012). Alternately, 20 mg/kg/dose as a single dose has been used (Red Book [AAP 2015]).

Shigellosis dysentery:

Non-HIV-exposed/-infected: Infants, Children, and Adolescents: Oral, immediate release: 15 mg/kg/dose twice daily for 3 days; maximum dose: 500 mg/dose (WHO 2005)

HIV-exposed-infected (HHS [adult] 2015): Adolescents: Duration of therapy: 7 to 10 days for gastroenteritis, at least 14 days for bacteremia, up to 6 weeks for recurrent infection

Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours

IV: Adolescents: 400 mg every 12 hours

Intra-abdominal infection, complicated: Infants, Children, and Adolescents: IV: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose (IDSA [Solomkin 2010])

Meningococcal invasive disease prophylaxis, high-risk contacts: Infants, Children, and Adolescents: Oral: Immediate release: 20 mg/kg as a single dose, maximum dose 500 mg/dose (Red Book [AAP 2015])

Mycobacterium avium Complex, severe or disseminated disease, HIV-exposed/-infected (HHS [pediatric] 2013): Infants and Children: Oral, immediate release: 10 to 15 mg/kg/dose twice daily in addition to other antibiotics; maximum dose: 750 mg/dose

Plague:

Manufacturer's labeling: Infants, Children, and Adolescents:

Oral, immediate release: 15 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum dose: 500 mg/dose

IV: 10 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum dose: 400 mg/dose

Alternate dosing (CDC [plague] 2015): Children and Adolescents:

Treatment:

Initial treatment: IV: 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose; continue until 2 days after fever subsides, then may change to oral therapy

Oral step-down to complete a 10 to 14 day course: Oral, immediate release: 20 mg/kg/dose twice daily; maximum dose: 500 mg/dose

Postexposure prophylaxis: Oral, immediate release: 20 mg/kg twice daily for 7 days; maximum dose: 500 mg/dose.

Pneumonia, community acquired (Haemophilus influenza): Infants >3 months and Children: IV: 15 mg/kg/dose every 12 hours (IDSA/PIDS [Bradley 2011a])

Salmonellosis, HIV-exposed/-infected (HHS [adult] 2015): Duration of therapy: At least 7 to 14 days if CD4 > 200 cells/mm2, 2 to 6 weeks if CD4 <200 cells/mm2

Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours

IV: Adolescents: 400 mg every 12 hours

Surgical prophylaxis: Children and Adolescents: IV: 10 mg/kg within 120 minutes prior to surgical incision; maximum dose: 400 mg/dose (ASHP [Bratzler 2013])

Tularemia, mild disease: Limited data available: Infants, Children, and Adolescents:

Treatment or contained casualty situation: IV: 15 mg/kg/dose twice daily for at least 10 days; maximum dose: 400 mg/dose (Dennis 2001; WHO 2007)

Prophylaxis, mass casualty situation: Oral, immediate release: 15 mg/kg/dose twice daily for 14 days; maximum dose: 500 mg/dose (Dennis 2001)

Urinary tract infection:

Cystitis, acute uncomplicated: Adolescents ≥ 18 years: Oral, extended release: 500 mg every 24 hours for 3 days

Complicated (including pyelonephritis):

Oral, immediate release: Children and Adolescents: 10 to 20 mg/kg/dose every 12 hours for 10 to 21 days; maximum dose: 750 mg/dose

Oral, extended release: Adolescents ≥18 years: 1,000 mg every 24 hours for 7 to 14 days

IV: Children and Adolescents: 6 to 10 mg/kg/dose every 8 hours for 10 to 21 days; maximum dose: 400 mg/dose

Dosing: Renal Impairment: Pediatric

Infants, Children, and Adolescents:

IV and Oral, immediate release: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007):

GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary

GFR 10 to 29 mL/minute/1.73 m2: 10 to 15 mg/kg/dose every 18 hours

GFR <10 mL/minute/1.73 m2: 10 to 15 mg/kg/dose every 24 hours

Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): Minimally dialyzable (<10%): 10 to 15 mg/kg/dose every 24 hours

CRRT: 10 to 15 mg/kg/dose every 12 hours

Oral, extended release: Adolescents ≥18 years:

CrCl ≥30 mL/minute: No dosage adjustment necessary

CrCl <30 mL/minute: 500 mg every 24 hours

Hemodialysis/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling; use with caution in severe impairment.

Calculations

• Creatinine Clearance by Cockcroft-Gault
• Creatinine Clearance by Cockcroft-Gault (SI units)
• Creatinine Clearance by Cockcroft-Gault with IBW
• Creatinine Clearance by Cockcroft-Gault with IBW (SI units)
• Creatinine Clearance by Jelliffe
• Creatinine Clearance by Sanaka
• Glomerular Filtration Rate by Abbreviated MDRD
• Glomerular Filtration Rate by Abbreviated MDRD (SI units)
• Glomerular Filtration Rate by MDRD
• Glomerular Filtration Rate by MDRD (IDMS-Traceable SCr)
• Glomerular Filtration Rate by MDRD (SI units)
• Glomerular Filtration Rate by Schwartz
• Glomerular Filtration Rate Estimate in African Americans by AASK Equation

Use: Labeled Indications

Children and Adolescents: Treatment of complicated urinary tract infections and pyelonephritis due to E. coli. Note: Although effective, ciprofloxacin is not the drug of first choice in children.

Infants, Children, Adolescents, and Adults: Prophylaxis to reduce incidence or progression of disease following inhalation exposure to Bacillus anthracis; prophylaxis and treatment of plague (Yersinia pestis).

Adults: Treatment of the following infections when caused by susceptible bacteria: Urinary tract infections; acute uncomplicated cystitis in females, chronic bacterial prostatitis, bone and joint infections, complicated intra-abdominal infections (in combination with metronidazole), infectious diarrhea, typhoid fever (Salmonella typhi), hospital-acquired (nosocomial) pneumonia.

Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve ciprofloxacin for use in patients who have no alternative treatment options for acute uncomplicated cystitis.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

AnthraxLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax, ciprofloxacin is an effective and recommended agent for treatment of cutaneous or systemic anthrax.

Bite wound infection (animal and human bites)Level of Evidence [G]

Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs), ciprofloxacin, in combination with an appropriate agent for anaerobes, is an effective and recommended alternative option for prophylaxis and treatment of human or animal bite wounds, particularly in patients who are hypersensitive to beta-lactams.

Cat scratch disease, lymphadenitis (nondisseminated)Level of Evidence [C]

Data from a limited number of patients suggest that ciprofloxacin may be beneficial for the treatment of cat scratch disease Ref.

Clinical experience suggests the utility of ciprofloxacin as an alternative agent in the treatment of cat scratch disease Ref.

ChancroidLevel of Evidence [G]

Based on the CDC sexually transmitted diseases treatment guidelines, ciprofloxacin is an effective and recommended alternative agent in the treatment of chancroid due to H. ducreyi. However, intermediate resistance to ciprofloxacin has been reported in several isolates. Potential resistance issues should be considered when initiating therapy for the treatment of chancroid.

Cholera (Vibrio cholerae)Level of Evidence [G]

Based on the CDC guidelines for cholera treatment with antibiotics, ciprofloxacin is an effective and recommended alternative agent for the treatment of moderate to severe cholera, in combination with aggressive hydration. Potential resistance issues should be considered when initiating therapy Ref.

Chronic obstructive pulmonary disease, acute exacerbationLevel of Evidence [A]

Data from a randomized, double-blind study support the use of ciprofloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) Ref. In addition, data from a smaller randomized study support the use of ciprofloxacin for treatment of acute exacerbations of COPD Ref.

Crohn disease, treatment of simple perianal fistulasLevel of Evidence [G]

Based on the American College of Gastroenterology guidelines for the management of Crohn disease in adults, ciprofloxacin (with or without metronidazole) is an effective and recommended treatment for patients with simple perianal fistulas.

Diabetic foot infectionLevel of Evidence [G]

Based on the IDSA guidelines for diagnosis and treatment of diabetic foot infections, ciprofloxacin, in combination with other appropriate agents, is an effective and recommended treatment option for diabetic foot infection.

Endocarditis, treatmentLevel of Evidence [G]

Based on the American Heart Association (AHA) scientific statement on infective endocarditis in adults, ciprofloxacin is an effective and recommended alternative treatment option for infective endocarditis (native or prosthetic valve) due to HACEK organisms (Haemophilus spp., Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens, and Kingella spp.) in patients unable to tolerate beta-lactam therapy.

Granuloma inguinale (donovanosis)Level of Evidence [G]

Based on the CDC sexually transmitted diseases treatment guidelines, ciprofloxacin is an effective and recommended alternative agent in the treatment of granuloma inguinale (donovanosis) when azithromycin is not appropriate.

Meningitis, bacterialLevel of Evidence [G]

Based on the IDSA guidelines for the management of bacterial meningitis and health care-associated ventriculitis and meningitis, ciprofloxacin is an effective and recommended alternative therapy for susceptible Pseudomonas aeruginosa meningitis; meningitis caused by susceptible multidrug-resistant gram-negative bacilli (in patients who have not responded to or cannot receive standard antimicrobial therapy); and health care-associated meningitis or ventriculitis requiring empiric therapy for gram-negative pathogens in patients with anaphylaxis to beta-lactams (in combination with other appropriate agents).

Meningococcal disease (prevention and control)Level of Evidence [G]

Based on the CDC guidelines for the prevention and control of meningococcal disease (Neisseria meningitidis), ciprofloxacin is an effective and recommended agent for management of this disease.

Neutropenia (chemotherapy-induced), antibacterial prophylaxisLevel of Evidence [G]

Based on IDSA guidelines for the use of antimicrobial agents in neutropenic patients with cancer, oral ciprofloxacin is effective and recommended for antibiotic prophylaxis in high-risk patients with expected durations of prolonged and profound neutropenia (ANC ≤100 cells/mm3 for >7 days). Based on the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program, the European Blood and Marrow Transplant Group, and multiple other organizations guidelines for preventing infectious complications among hematopoietic cell transplant (HCT) recipients, oral ciprofloxacin may be used in adult HCT recipients to prevent bacterial infections in the first 100 days after transplant when the anticipated period of neutropenia is ≥7 days.

Neutropenic fever, low-risk cancer patients (empiric therapy)Level of Evidence [A, G]

Data from 3 randomized trials (blinding varied) support the use of oral ciprofloxacin (in combination with amoxicillin and clavulanate) for the outpatient empiric management of low-risk neutropenic fever Ref. The American Society of Clinical Oncology (ASCO) and IDSA guidelines for outpatient management of fever and neutropenia in adults treated for malignancy and the IDSA guidelines for use of antimicrobial agents in neutropenic patients with cancer also support oral ciprofloxacin use (in combination with amoxicillin and clavulanate) in this patient population. Use should be avoided in patients who have received fluoroquinolone prophylaxis.

Peritoneal dialysis catheter-related infectionLevel of Evidence [G]

Based on the International Society for Peritoneal Dialysis catheter-related infection recommendations, ciprofloxacin is an effective and recommended agent for the management of peritoneal dialysis catheter exit-site or tunnel infection.

Peritonitis, spontaneous bacterial (prevention)Level of Evidence [B, G]

Limited data from controlled trials support use of ciprofloxacin as an alternative to norfloxacin for primary long-term prophylaxis in cirrhotic patients with low protein ascites, or as secondary long-term prophylaxis in patients who have experienced a prior spontaneous bacterial peritonitis (SBP) episode. Additional trials may be necessary to further define the role of ciprofloxacin in the prevention of SBP.

According to AASLD and EASL guidelines, ciprofloxacin is suggested as an alternative to norfloxacin; however, recommendations regarding the use of daily or weekly dosing vary. The AASLD prefers daily dosing, given the risk of increasing quinolone bacterial resistance rates with weekly dosing. Increasing bacterial resistance rates to antibiotics used in the treatment and prevention of SBP have been documented; therefore, local epidemiological patterns should be considered, and use of antibiotic prophylaxis should be restricted to patients at high risk of SBP. Access Full Off-Label Monograph

Prostatitis, acute bacterialLevel of Evidence [C]

Data from a limited number of patients studied suggest that ciprofloxacin may be beneficial for the treatment of acute bacterial prostatitis Ref.

Clinical experience also suggests the utility of ciprofloxacin in the treatment of acute bacterial prostatitis Ref.

Prosthetic joint infectionLevel of Evidence [G]

Based on the IDSA guidelines for the management of prosthetic joint infection, ciprofloxacin is an effective and recommended agent for treatment of prosthetic joint infection with either Pseudomonas aeruginosa, Enterobacter spp, or Enterobacteriaceae. Ciprofloxacin is also an effective and recommended agent for indefinite oral antimicrobial suppression of Pseudomonas aeruginosa. Ciprofloxacin, in combination with rifampin, is also an effective and recommended agent for oral phase treatment of prosthetic joint infection with staphylococci after completion of parenteral therapy.

Surgical prophylaxisLevel of Evidence [G]

Based on the American Society of Health-System Pharmacists (ASHP), the IDSA, the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology of America (SHEA) guidelines for antimicrobial prophylaxis in surgery, ciprofloxacin is an effective and recommended agent for prophylaxis of certain surgical procedures (eg, gastroduodenal, biliary tract, appendectomy, hysterectomy, and some urologic procedures) when allergy to beta-lactams exist and is a recommended agent for lower urologic tract instrumentation in patients with risk factors for infection (including transrectal prostate biopsy).

Surgical site infectionLevel of Evidence [G]

Based on the IDSA guidelines for the diagnosis and management of SSTIs, ciprofloxacin, in combination with metronidazole, is an effective and recommended option for treatment of surgical site infections occurring after surgery of the intestinal or genitourinary tract, perineum, or axilla. Systemic antibacterials are not routinely indicated for surgical site infections, but may be beneficial (in conjunction with suture removal plus incision and drainage) in patients with significant systemic response (eg, temperature >38.5°C, heart rate >110 beats per minute, erythema/induration extending >5 cm from incision, WBC >12,000/mm3).

TularemiaLevel of Evidence [C, G]

Data from retrospective studies and case reports/series demonstrate varied results with the use of ciprofloxacin in the management of tularemia. Guidelines created by the Infectious Diseases Society of America, Working Group on Civilian Biodefense, and the European Commission's Task Force on Biological and Chemical Agent Threats (BICHAT) recommend ciprofloxacin as an alternative in the management of mild tularemia infection. In scenarios of mass casualty management and postexposure prophylaxis, the Working Group on Civilian Biodefense considers oral ciprofloxacin and doxycycline as drugs of choice. Access Full Off-Label Monograph

Level of Evidence Definitions

Level of Evidence Scale

Use: Unsupported: Adult

Gonorrhea

Although included as an FDA-approved use in the manufacturer's prescribing information for the treatment of uncomplicated cervical and urethral gonorrhea, clinical practice guidelines do not recommend ciprofloxacin for the treatment of gonorrhea because of widespread resistance (CDC [Workowski 2015]).

Lower respiratory tract infection (acute bronchitis)

Although included as an FDA-approved use in the manufacturer's prescribing information, ciprofloxacin is not recommended empirically for healthy adults (without chronic lung disease or immunosuppression) for the treatment of lower respiratory tract infection (acute bronchitis) (ACP/CDC [Harris 2016]). Additionally, the FDA recommends that ciprofloxacin be reserved for patients who have no alternative treatment options in the treatment of bronchitis (FDA 2016).

Sinusitis (acute)

Although included as an FDA-approved use in the manufacturer's prescribing information, ciprofloxacin is not recommended empirically for the treatment of sinusitis (Rosenfeld 2015). Additionally, the FDA recommends that ciprofloxacin be reserved for patients who have no alternative treatment options in the treatment of sinusitis (FDA 2016).

Skin and soft tissue infection

Although included as an FDA-approved use in the manufacturer's prescribing information, ciprofloxacin is not recommended for empiric treatment of uncomplicated skin and soft tissue infection since the majority are due to gram-positive bacteria (IDSA [Stevens 2014]).

Class and Related Monographs

Fluoroquinolones

Clinical Practice Guidelines

Ascites:

AASLD Practice Guidelines: “Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012,” 2012

Chronic Obstructive Pulmonary Disease:

GOLD, “Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease”, 2019

Crohn Disease:

ACG, “Management of Crohn's Disease in Adults,” 2018

Diabetic Foot Infection:

IDSA, “The Diagnosis and Treatment of Diabetic Foot Infections,” 2012

Drug-Induced Liver Injury:

American College of Gastroenterology (ACG), “2014 ACG Guideline for Idiosyncratic Drug-induced Liver Injury,” July 2014

Infective Endocarditis:

AHA, “Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications,” October 2015

British Society for Antimicrobial Chemotherapy (BSAC), "Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults," 2012

Intra-abdominal Infection:

IDSA, “Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children,” January 2010

Meningitis, bacterial:

IDSA, "Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis," February 2017

IDSA, "Practice Guidelines for the Management of Bacterial Meningitis," October 2004

Neutropenic Fever:

ASCO/IDSA, “Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update,” February 2018

IDSA, “Use of Antimicrobial Agents in Neutropenic Patients with Cancer,” February 2011

Oncology:

ASBMT/IDSA/SHEA, “Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplant Recipients,” October 2009

Opportunistic Infections:

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children, November 2013. Note: Information contained within this monograph is pending revision based on these more recent guidelines.

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Osteomyelitis:

IDSA, "Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults," 2015

Pneumonia, Community-Acquired:

IDSA/PIDS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age," 2011

Pneumonia, Hospital-Acquired and Ventilator-Associated

IDSA/ATS, "Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia," July 2016

Prosthetic Joint Infection:

IDSA, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline,” January 2013

Sexually-Transmitted Disease:

CDC, “Sexually Transmitted Diseases Treatment Guidelines,” June 2015.

Shigellosis:

World Health Organization, “Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae type 1”, 2005

Skin and Soft-tissue Infection:

IDSA, “Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections,” June 2014

Surgical Prophylaxis:

ASHP, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” February 2013

Traveler's Diarrhea:

American College of Gastroenterology (ACG), “ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults,” May 2016

CDC, “The Yellowbook: Travelers’ Diarrhea,” 2018

IDSA, "2017 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Management of Infectious Diarrhea,” 2017

Urinary Tract Infections:

IDSA, “International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women,” March 2011

Urinary Tract Infections, Catheter-Related:

IDSA, “Diagnosis, Prevention, and Treatment of Catheter- Associated Urinary Tract Infection in Adults,” February 2010

Administration: IV

Administer by slow IV infusion over 60 minutes into a large vein (reduces risk of venous irritation).

Administration: Injectable Detail

pH: 3.3 to 3.9 (vials); 3.5 to 4.6 (PVC bags)

Administration: Oral

May administer with most foods to minimize GI upset; avoid antacid use; maintain proper hydration and urine output. Avoid concomitant administration with dairy products (eg, milk, yogurt) or calcium-fortified juices alone, however, may be taken with meals that contain these products; separate administration of Cipro XR and calcium >800 mg by at least 2 hours. Administer immediate-release ciprofloxacin and Cipro XR at least 2 hours before or 6 hours after antacids or other products containing calcium, iron, or zinc. Separate oral administration from drugs that may impair absorption (see Drug Interactions).

Oral suspension: Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Shake vigorously before use for ~15 seconds; administer using the co-packaged graduated teaspoon. Do not chew the microcapsules in the suspension; swallow whole.

Nasogastric/orogastric tube: Crush immediate-release tablet and mix with 20 to 60 mL water. Flush feeding tube before and after administration. Do not administer simultaneously with enteral nutrition (Beckwith 2004; Healy 1996). Optimal time frame for dose separation is unknown; one recommendation is to hold tube feedings at least 2 hours before and 4 hours after administration, which may require adjustment of feeding rates to compensate for lost feeding time (Beckwith 2004).

Tablet, extended release: Do not crush, split, or chew.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation (tablet or oral solution).

Administration: Pediatric

Oral: May administer with food to minimize GI upset; divalent and trivalent cations [dairy foods (milk, yogurt) and mineral supplements (eg, iron, zinc, calcium) or calcium-fortified juices] decrease ciprofloxacin absorption; usual dietary calcium intake (including meals which include dairy products) has not been shown to interfere with ciprofloxacin absorption (per manufacturer). Administer immediate release ciprofloxacin and Cipro XR at least 2 hours before or 6 hours after any of these products.

Oral suspension: Shake vigorously prior to each dose. Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Patients should avoid chewing on the microcapsules.

Tablets:

Immediate release: Administering 2 hours after meals is preferable.

Extended release: Do not crush, split, or chew. May be administered with meals containing dairy products (calcium content <800 mg), but not with dairy products alone.

Nasogastric/orogastric tube: Crush immediate release tablet and mix with water. Flush feeding tube before and after administration. Hold tube feedings at least 1 hour before and 2 hours after administration.

Parenteral: Administer by slow IV infusion over 60 minutes to reduce the risk of venous irritation (burning, pain, erythema, and swelling)

Dietary Considerations

Food: May be taken with meals that contain dairy products (eg, milk, yogurt) or calcium-fortified juices, but not with these products alone; separate administration of Cipro XR and calcium >800 mg by at least 2 hours.

Caffeine: Patients consuming regular large quantities of caffeinated beverages may need to restrict caffeine intake if excessive cardiac or CNS stimulation occurs.

Storage/Stability

Injection:

Premixed infusion: Store between 5°C to 25°C (41°F to 77°F); avoid freezing. Protect from light.

Vial: Store between 5°C to 30°C (41°F to 86°F); avoid freezing. Protect from light. Diluted solutions of 0.5 to 2 mg/mL in D51/4NS, D51/2NS, D5W, D10W, LR, NS are stable for up to 14 days refrigerated or at room temperature.

Microcapsules for oral suspension: Prior to reconstitution, store below 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from freezing. Following reconstitution, store at 25°C (77°F) for 14 days; excursions permitted to 15°C to 30°C (59°F to 86°F) for up to 14 days. Protect from freezing.

Tablet:

Immediate release: Store between 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Extended release: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).

Preparation for Administration: Adult

Injection, vial: May be diluted with NS, D5W, SWFI, D10W, D51/4NS, D51/2NS, LR to a final concentration not to exceed 2 mg/mL.

Preparation for Administration: Pediatric

Oral: Reconstitute powder for oral suspension with appropriate amount of water as specified on the bottle. Shake vigorously until suspended.

Parenteral: May be diluted with NS, D5W, SWFI, D10W, D51/4NS, D51/2NS, LR to a final concentration not to exceed 2 mg/mL

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Extemporaneously Prepared

A 50 mg/mL oral suspension may be made using 2 different vehicles (a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Methylcellulose 1% and Simple Syrup, NF). Crush twenty 500 mg tablets and reduce to a fine powder. Add a small amount of vehicle and mix to a uniform paste; mix while adding the vehicle in geometric proportions to almost 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label "shake well" and "refrigerate". Stable 91 days refrigerated and 70 days at room temperature. Note: Microcapsules for oral suspension available (50 mg/mL; 100 mg/mL); not for use in feeding tubes.

Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat or prevent bacterial infections.

Frequently reported side effects of this drug

• Diarrhea

• Vomiting

• Nausea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Tendon inflammation or rupture like pain, bruising, or swelling in the back of the ankle, shoulder, hand, or other joints

• Depression like thoughts of suicide, anxiety, emotional instability, agitation, irritability, panic attacks, mood changes, behavioral changes, or confusion

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin.

• Kidney problems like unable to pass urine, blood in the urine, change in amount of urine passed, or weight gain

• Nerve problems like sensitivity to heat or cold; decreased sense of touch; burning, numbness, or tingling; pain, or weakness in the arms, hands, legs, or feet

• Low blood sugar like dizziness, headache, fatigue, feeling weak, shaking, fast heartbeat, confusion, increased hunger, or sweating

• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit

• Fast heartbeat

• Abnormal heartbeat

• Passing out

• Chest pain

• Thrush

• Severe loss of strength and energy

• Vision changes

• Sensing things that seem real but are not

• Seizures

• Severe headache

• Trouble sleeping

• Nightmares

• Dizziness

• Restlessness

• Shortness of breath

• Bruising

• Bleeding

• Tremors

• Abnormal gait

• Sunburn

• Chills

• Sore throat

• Vaginal pain, itching, and discharge

• Muscle pain

• Muscle weakness

• Difficulty focusing

• Trouble with memory

• Injection site irritation

• Severe or persistent pain in abdomen

• Severe or persistent chest pain

• Severe or persistent back pain

• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Cipro: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019857s070lbl.pdf#page=33

Contraindications

Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones; concurrent administration of tizanidine

Canadian labeling: Additional contraindications (not in the US labeling): Concurrent administration of agomelatine

Warnings/Precautions

Concerns related to adverse effects:

• Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with a history of or at risk for QTc prolongation, torsades de pointes, uncorrected electrolyte disorders (hypokalemia or hypomagnesemia), cardiac disease (heart failure, myocardial infarction, bradycardia) or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).

• Aortic aneurysm and dissection: Fluoroquinolones have been associated with aortic aneurysm ruptures or dissection within 2 months following use, particularly in elderly patients. Fluoroquinolones should not be used in patients with a known history of aortic aneurysm or those at increased risk, including patients with peripheral atherosclerotic vascular diseases, hypertension, genetic disorders involving blood vessel changes (eg, Marfan syndrome, Ehlers-Danlos syndrome), and elderly patients, unless no other treatment options are available. Longer treatment duration (eg, >14 days) may increase risk (Lee 2018).

• Crystalluria: Rarely, crystalluria has occurred; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.

• Glucose regulation: Fluoroquinolones have been associated with disturbances in glucose regulation, including hyperglycemia and hypoglycemia. These events have occurred most often in patients receiving concomitant oral hypoglycemic agents or insulin. Severe cases of hypoglycemia, including coma and death, have been reported. Diabetic patients should be monitored closely for signs/symptoms of disordered glucose regulation. Discontinue if a hypoglycemic reaction occurs and immediately initiate appropriate therapy.

• Hepatotoxicity: Hepatocellular, cholestatic, or mixed liver injury has been reported, including hepatic necrosis, life-threatening hepatic events, and fatalities. Acute liver injury can be rapid onset (range: 1 to 39 days) and is often associated with hypersensitivity. The pattern of injury can be hepatocellular, cholestatic, or mixed. Most fatalities occurred in patients >55 years of age. Discontinue immediately if signs/symptoms of hepatitis (abdominal tenderness, dark urine, jaundice, pruritus) occur. Additionally, temporary increases in transaminases or alkaline phosphatase, or cholestatic jaundice may occur (highest risk in patients with previous liver damage).

• Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with fluoroquinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatitis, jaundice, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.

• Photosensitivity/phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions which may appear as exaggerated sunburn reactions. Discontinue use if phototoxicity occurs.

• Serious adverse reactions: [US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions. Patients of any age or without preexisting risk factors have experienced these reactions; may occur within hours to weeks after initiation.

- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects, including seizures, increased intracranial pressure (including pseudotumor cerebri), dizziness, and tremors. Status epilepticus cases have been reported. Use with caution in patients with a history of seizures, with known or suspected CNS disorder (severe cerebral arteriosclerosis, previous history of convulsion, reduced cerebral blood flow, altered brain structure, or stroke), or with other risk factors that may predispose to seizures or lower the seizure threshold (eg, certain drug therapy, renal dysfunction). Discontinue if seizures occur and institute appropriate therapy.

- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue immediately if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.

- Psychiatric reactions: Fluoroquinolones have been associated with an increased risk of psychiatric reactions, including toxic psychosis, hallucinations, or paranoia; may also cause nervousness, agitation, delirium, attention disturbances, insomnia, anxiety, nightmares, memory impairment, confusion, depression, and suicidal thoughts or actions. Use with caution in patients with a history of or risk factor for mental illness. Reactions may appear following the first dose; discontinue if reaction occurs and institute appropriate therapy.

- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients >60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Myasthenia gravis: [US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with a known history of myasthenia gravis. Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.

• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.

• Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.

• Syphilis: Since ciprofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.

• Pediatric: Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children (exception is anthrax treatment).

Other warnings/precautions:

• Appropriate use: [US Boxed Warning]: Reserve use of ciprofloxacin for treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or acute uncomplicated cystitis for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Ciprofloxacin should not be used as first-line therapy unless the culture and sensitivity findings show resistance to usual therapy. The interactions with caffeine and theophylline can result in serious toxicity in the elderly. Adjust dose for renal function. The risk of torsade de pointes and tendon inflammation and/or rupture associated with the concomitant use of corticosteroids and quinolones is increased in the elderly population. See Warnings/Precautions regarding tendon rupture in patients >60 years of age.

Warnings: Additional Pediatric Considerations

Increased osteochondrosis in immature rats and dogs was observed with ciprofloxacin and fluoroquinolones have caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals. In an international safety data analysis of ciprofloxacin in approximately 700 pediatric patients (1 to 17 years), the follow-up arthropathy rate at 6 weeks and cumulative arthropathy rate at 1 year were higher in ciprofloxacin treatment group than comparative controls (6 weeks: 9.3% vs 6%; 1 year: 13.7% to 9.5%). In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, resistance [anthrax, common CF pathogens, multidrug resistant tuberculosis]) or in situations where the only alternative is parenteral therapy and ciprofloxacin offers an oral therapy option (Bradley 2011b).

Pregnancy Risk Factor

C

Pregnancy Considerations

Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam 1997). Based on available data, an increased risk of teratogenic effects has not been observed following ciprofloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014). Ciprofloxacin is recommended for prophylaxis and treatment of pregnant women exposed to anthrax (Meaney-Delman 2014). Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989).

Breast-Feeding Considerations

Ciprofloxacin is present in breast milk.

The relative infant dose (RID) of ciprofloxacin is 2.8% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 20 mg/kg/day.

In general, breastfeeding is considered acceptable when the relative infant dose is <10% (Anderson 2016; Ito 2000).

Using the highest average milk concentration (3.79 mcg/mL), the estimated daily infant dose via breast milk is 0.569 mg/kg/day. This milk concentration was obtained following a maternal dose of ciprofloxacin 750 mg every 12 hours for 3 doses (n=10) (Giamarellou 1989).

There is a case report of perforated pseudomembranous colitis in a breastfeeding infant whose mother was taking ciprofloxacin (Harmon 1992). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).

Ciprofloxacin is recommended for the prophylaxis and treatment of Bacillus anthracis in breastfeeding women (Meaney-Delman 2014). Alternative agents are recommended in nursing women for the treatment of chancroid (CDC [Workowski 2015]). The manufacturer does not recommend use of ciprofloxacin in breastfeeding women due to concerns of potential articular damage; however, this risk is considered low even in children receiving high therapeutic doses. Therefore, some sources do not consider maternal use of ciprofloxacin to be a reason to discontinue nursing as long as the infant is monitored for gastrointestinal symptoms (eg, diarrhea) which could occur following antibiotic exposure (Kaplan 2015). Other sources recommend avoiding quinolone antibiotics if alternative agents are available (WHO 2002).

Lexicomp Pregnancy & Lactation, In-Depth

• Ciprofloxacin (Systemic)

Briggs' Drugs in Pregnancy & Lactation

• Ciprofloxacin

Adverse Reactions

>10%: Neuromuscular & skeletal: Musculoskeletal signs and symptoms (children: 9% to 22%)

1% to 10%:

Dermatologic: Skin rash (1% to 2%)

Gastrointestinal: Diarrhea (2% to 5%), vomiting (1% to 5%), nausea (3% to 4%), abdominal pain (children: 3%; adults: <1%), dyspepsia (1% to 3%)

Genitourinary: Vulvovaginal candidiasis (2%)

Hepatic: Abnormal hepatic function tests (1%), increased serum aspartate aminotransferase (1%), increased serum alanine aminotransferase

Local: Injection site reactions (IV: >1%)

Nervous system: Neurological signs and symptoms (IV: children: 3%), headache (oral: 1% to 3%; IV: >1%), dizziness (oral: 2%; IV: <1%), restlessness (IV: >1%; oral: <1%), insomnia, nervousness, somnolence

Respiratory: Asthma (children: 2%)

Miscellaneous: Fever (children: 2%; adults: <1%)

<1%: Abdominal distress, abnormal dreams, abnormal gait, acute myocardial infarction, acute renal failure, agranulocytosis, albuminuria, anaphylactic shock, anaphylaxis, angina pectoris, angioedema, anorexia, anosmia, arthralgia, asthenia, ataxia, blurred vision, bradycardia, bronchospasm, burning sensation, casts in urine, cholestatic jaundice, chromatopsia, Clostridioides difficile colitis, confusion, constipation, crystalluria, decreased prothrombin time, decreased visual acuity, depersonalization, depression, dermatologic disorders, diaphoresis, diplopia, drowsiness, dysgeusia, dysmenorrhea, dyspnea, erythema multiforme, erythema nodosum, exfoliative dermatitis, flatulence, flushing, gastrointestinal hemorrhage, gynecomastia, hallucination, hearing loss, hematuria, hemoptysis, hemorrhagic cystitis, hepatic necrosis, hepatitis, hyperglycemia, hypersensitivity reaction, hypertension, hypertonia, hypoglycemia, hypotension, increased thirst, interstitial nephritis, intestinal obstruction, intestinal perforation, irritability, joint stiffness, laryngeal edema, maculopapular rash, malaise, manic reaction, migraine, myasthenia, nephrolithiasis, nightmares, nystagmus disorder, oral mucosa ulcer, pain, pancreatitis, paranoid ideation, paresthesia, petechia, phobia, photopsia, phototoxicity, prolonged prothrombin time, pruritus, purpuric disease, renal insufficiency, seizure, skin photosensitivity, status epilepticus, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, syncope, tachycardia, taste disorder, thrombophlebitis, tinnitus, toxic epidermal necrolysis, toxic psychosis, tremor, unresponsive to stimuli, urinary frequency, urticaria, vaginitis, vasculitis, vasodilation, vertigo, vesicobullous dermatitis, visual disturbance, xeroderma, xerostomia

Postmarketing: Acute generalized exanthematous pustulosis, ageusia, agitation, anemia, anxiety, bleeding tendency disorder, candidiasis, Clostridioides difficile associated diarrhea, decreased serum albumin, decreased serum potassium, decreased serum total protein, delirium, disturbance in attention, eosinophilia, exacerbation of myasthenia gravis, fixed drug eruption, hemolytic anemia, hepatic failure, hepatotoxicity, hyperesthesia, hypoesthesia, hypouricemia, idiopathic intracranial hypertension, increased blood urea nitrogen, increased creatine phosphokinase in blood specimen, increased erythrocyte sedimentation rate, increased gamma-glutamyl transferase, increased intracranial pressure, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum amylase, increased serum bilirubin, increased serum calcium, increased serum cholesterol, increased serum creatinine, increased serum potassium, increased serum triglycerides, increased uric acid, intracranial hypertension (Tan 2019), jaundice, leukocytosis, leukopenia, lymphocytosis, memory impairment, methemoglobinemia, monocytosis, myalgia, myoclonus, pancytopenia, peripheral neuropathy, pneumonitis, polyneuropathy, prolonged QT interval on ECG, rupture of tendon, serum sickness-like reaction, tendonitis, thrombocythemia, thrombocytopenia, torsades de pointes, twitching, ventricular arrhythmia

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Fluoroquinolone Allergy

Metabolism/Transport Effects

Substrate of OAT1/3, P-glycoprotein/ABCB1; Inhibits CYP1A2 (moderate), CYP3A4 (weak)

Drug Interactions Open Interactions

Agents with Blood Glucose Lowering Effects: Quinolones may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Agomelatine: Ciprofloxacin (Systemic) may increase the serum concentration of Agomelatine. Risk X: Avoid combination

Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. Management: Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors whenever possible. If combined use is necessary, monitor for increased alosetron effects/toxicities. Risk D: Consider therapy modification

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy

Amphetamines: May enhance the cardiotoxic effect of Quinolones. Risk C: Monitor therapy

Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone. Exceptions: Sodium Bicarbonate. Risk D: Consider therapy modification

ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations. Risk C: Monitor therapy

Asenapine: Ciprofloxacin (Systemic) may increase the serum concentration of Asenapine. Risk C: Monitor therapy

Ataluren: May increase the serum concentration of Ciprofloxacin (Systemic). Risk C: Monitor therapy

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Bendamustine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bendamustine. Management: Consider alternatives to moderate CYP1A2 inhibitors during therapy with bendamustine due to the potential for increased bendamustine plasma concentrations and increased bendamustine toxicity. Risk D: Consider therapy modification

Bromazepam: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Bromazepam. Risk C: Monitor therapy

Caffeine and Caffeine Containing Products: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor therapy

Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Exceptions: Calcium Chloride. Risk D: Consider therapy modification

CarBAMazepine: Ciprofloxacin (Systemic) may increase the serum concentration of CarBAMazepine. Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

ClomiPRAMINE: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. Risk C: Monitor therapy

CloZAPine: Ciprofloxacin (Systemic) may enhance the QTc-prolonging effect of CloZAPine. Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine. Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity. Resume the previous clozapine dose following ciprofloxacin discontinuation. Risk D: Consider therapy modification

Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. Risk C: Monitor therapy

Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid. Management: Avoid concomitant use if possible. If coadministration is unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur. Exceptions are discussed in separate monographs. Risk D: Consider therapy modification

Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine. Risk D: Consider therapy modification

Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. Risk C: Monitor therapy

DULoxetine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of DULoxetine. Risk C: Monitor therapy

Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements). Risk D: Consider therapy modification

Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. Risk C: Monitor therapy

Fosphenytoin: May enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin. Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. Risk C: Monitor therapy

Iron Preparations: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron. Exceptions: Ferric Carboxymaltose; Ferric Derisomaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose. Risk D: Consider therapy modification

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum. Risk D: Consider therapy modification

Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider therapy modification

Lomitapide: Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. Risk X: Avoid combination

Lumateperone: Ciprofloxacin (Systemic) may increase the serum concentration of Lumateperone. Risk C: Monitor therapy

Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts. Risk D: Consider therapy modification

Melatonin: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Melatonin. Risk C: Monitor therapy

Meptazinol: May decrease the serum concentration of Ciprofloxacin (Systemic). Risk X: Avoid combination

Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate. Risk C: Monitor therapy

Methylphenidate: May enhance the cardiotoxic effect of Quinolones. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc). Risk D: Consider therapy modification

Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc). Risk D: Consider therapy modification

Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. Risk C: Monitor therapy

Nadifloxacin: May enhance the adverse/toxic effect of Quinolones. Risk X: Avoid combination

NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Nitisinone: May increase the serum concentration of OAT1/3 Substrates. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. Risk C: Monitor therapy

OLANZapine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of OLANZapine. Risk C: Monitor therapy

Olaparib: Ciprofloxacin (Systemic) may increase the serum concentration of Olaparib. Risk C: Monitor therapy

Patiromer: May decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer. Risk D: Consider therapy modification

Pentoxifylline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pentoxifylline. Risk C: Monitor therapy

Phenytoin: Ciprofloxacin (Systemic) may diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin. Risk C: Monitor therapy

Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Pirfenidone: Ciprofloxacin (Systemic) may increase the serum concentration of Pirfenidone. Management: With ciprofloxacin doses of 1,500 mg/day, the pirfenidone dose should be reduced to 1,602 mg per (534 mg three times a day). With lower daily doses of ciprofloxacin, use pirfenidone with caution. Risk D: Consider therapy modification

Pomalidomide: Ciprofloxacin (Systemic) may increase the serum concentration of Pomalidomide. Management: Avoid concomitant use of pomalidomide and ciprofloxacin when possible. If coadministration is considered necessary, consider reducing the pomalidomide dose 50% and monitoring patients for increased pomalidomide effects/toxicities. Risk D: Consider therapy modification

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy

Pretomanid: May increase the serum concentration of OAT1/3 Substrates. Risk C: Monitor therapy

Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones. Risk C: Monitor therapy

Propranolol: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Propranolol. Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly. Risk D: Consider therapy modification

Ramelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. Risk C: Monitor therapy

Ramosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ramosetron. Risk C: Monitor therapy

Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. Management: Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors. Risk D: Consider therapy modification

Roflumilast: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast. Risk C: Monitor therapy

ROPINIRole: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of ROPINIRole. Risk C: Monitor therapy

Ropivacaine: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Ropivacaine. Risk C: Monitor therapy

Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer. Risk D: Consider therapy modification

Sildenafil: Ciprofloxacin (Systemic) may increase the serum concentration of Sildenafil. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Spironolactone: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). Risk C: Monitor therapy

Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy. Risk X: Avoid combination

Sucralfate: May decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone. Risk D: Consider therapy modification

Tasimelteon: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Tasimelteon. Risk C: Monitor therapy

Teriflunomide: May increase the serum concentration of OAT1/3 Substrates. Risk C: Monitor therapy

Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern. Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. Exceptions: Dyphylline. Risk D: Consider therapy modification

Theophylline Derivatives: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Theophylline Derivatives. Management: Consider avoidance of this combination. If coadministration is necessary, monitor for increased theophylline serum concentrations and toxicities when combined. Theophylline dose reductions will likely be required. Exceptions: Dyphylline. Risk D: Consider therapy modification

Thyroid Products: Ciprofloxacin (Systemic) may decrease the serum concentration of Thyroid Products. Risk C: Monitor therapy

TiZANidine: Ciprofloxacin (Systemic) may increase the serum concentration of TiZANidine. Risk X: Avoid combination

Tolvaptan: May increase the serum concentration of OAT1/3 Substrates. Management: Avoid concomitant use of OAT1/3 substrates in patients receiving the Jynarque brand of tolvaptan. Concentrations and effects of the OAT1/3 substrate would be expected to increase with combined use. Risk D: Consider therapy modification

Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. Management: Consider triazolam dose reduction in patients receiving concomitant weak CYP3A4 inhibitors. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Risk D: Consider therapy modification

Ubrogepant: Ciprofloxacin (Systemic) may increase the serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 50 mg and consider avoiding a second dose for 24 hours when used with ciprofloxacin. Risk D: Consider therapy modification

Varenicline: Quinolones may increase the serum concentration of Varenicline. Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling. Risk C: Monitor therapy

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts. Exceptions: Zinc Chloride. Risk D: Consider therapy modification

Zolpidem: Ciprofloxacin (Systemic) may increase the serum concentration of Zolpidem. Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy). Risk D: Consider therapy modification

Food Interactions

Food decreases rate, but not extent, of absorption. Ciprofloxacin may increase serum caffeine levels if taken concurrently. Rarely, crystalluria may occur. Enteral feedings may decrease plasma concentrations of ciprofloxacin probably by >30% inhibition of absorption. Management: May administer with most foods to minimize GI upset. If unable to avoid the following foods, administer ciprofloxacin at least 2 hours before or 6 hours after dairy products or calcium-fortified juices alone or in a meal containing >800 mg calcium. Restrict caffeine intake if excessive cardiac or CNS stimulation occurs. Ensure adequate hydration during therapy. Ciprofloxacin should not be administered with enteral feedings. The feeding would need to be discontinued for 1 to 2 hours prior to and after ciprofloxacin administration. Nasogastric administration produces a greater loss of ciprofloxacin bioavailability than does nasoduodenal administration.

Test Interactions

Some quinolones may produce a false-positive urine screening result for opioids using commercially-available immunoassay kits. This has been demonstrated most consistently for levofloxacin and ofloxacin, but other quinolones have shown cross-reactivity in certain assay kits. Confirmation of positive opioid screens by more specific methods should be considered.

Monitoring Parameters

CBC, renal and hepatic function during prolonged therapy, altered mental status, signs and symptoms of tendonitis; signs and symptoms of disordered glucose regulation

Advanced Practitioners Physical Assessment/Monitoring

Assess results of culture and sensitivity tests prior to beginning therapy. Obtain CBC, renal function tests, and liver function tests with prolonged therapy. Assess risk vs benefit in patients with or at risk for altered cardiac conduction, mental illness, or aortic aneurysm. Screen patients for diabetes, history of liver dysfunction, history of peripheral neuropathy, myasthenia gravis, rheumatoid arthritis, and syphilis. Assess for signs and symptoms of CNS effects. Assess for signs and symptoms of tendonitis. Test for C. difficile if patient develops diarrhea.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Monitor for hypersensitivity reactions (severe reactions, including anaphylaxis, have occurred with quinolone therapy). Instruct patient to report signs and symptoms of tendonitis (pain or swelling of joints, unable to bear weight on a joint, or feeling a snap or pop). Educate patient to report any signs of altered mental status (anxiety, nightmares, agitation, hallucinations, suicidal ideation, or behavioral changes). Monitor for severe or bloody diarrhea and send a specimen to the lab for C. difficile. Monitor for improvement of infection. Instruct diabetic patients to monitor glucose levels carefully while on this drug. Instruct patients with myasthenia gravis to report any increased muscle weakness. Instruct patients to report signs of sensory or sensorimotor neuropathy immediately. Educate patients about proper sun protection; can burn more easily. Educate patients regarding timing of dosage with regard to meals, dairy products, and antacids. Maintain adequate hydration unless fluid restriction is in place.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Generic: 200 mg/100 mL (100 mL [DSC]); 400 mg/200 mL (200 mL [DSC])

Solution, Intravenous [preservative free]:

Cipro in D5W: 400 mg/200 mL (200 mL [DSC]) [latex free]

Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL); 200 mg/20 mL (20 mL [DSC]); 400 mg/40 mL (40 mL [DSC])

Suspension Reconstituted, Oral:

Cipro: 250 mg/5 mL (100 mL); 500 mg/5 mL (100 mL) [strawberry flavor]

Generic: 250 mg/5 mL (100 mL [DSC]); 500 mg/5 mL (100 mL [DSC])

Tablet, Oral, as hydrochloride [strength expressed as base]:

Cipro: 250 mg, 500 mg

Generic: 100 mg, 250 mg, 500 mg, 750 mg

Tablet Extended Release 24 Hour, Oral, as base and hydrochloride [strength expressed as base]:

Cipro XR: 500 mg [DSC], 1000 mg [DSC]

Generic: 500 mg [DSC], 1000 mg [DSC]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Generic: 10 mg/mL ([DSC]); 2 mg/mL in D5W (100 mL, 200 mL)

Suspension Reconstituted, Oral:

Cipro: 500 mg/5 mL (100 mL) [contains soybean lecithin]

Tablet, Oral, as hydrochloride [strength expressed as base]:

Cipro: 250 mg [DSC], 500 mg, 750 mg [DSC] [contains corn starch]

Generic: 100 mg, 250 mg, 500 mg, 750 mg

Tablet Extended Release 24 Hour, Oral, as base and hydrochloride [strength expressed as base]:

Cipro XL: 500 mg, 1000 mg

Generic: 500 mg

Anatomic Therapeutic Chemical (ATC) Classification

• J01MA02

Generic Available (US)

Yes

Pricing: US

Solution (Ciprofloxacin in D5W Intravenous)

200 mg/100 mL (per mL): $0.02 - $0.15

400 mg/200 mL (per mL): $0.02 - $0.14

Suspension (reconstituted) (Cipro Oral)

250 MG/5ML (5%) (per mL): $1.56

500 MG/5ML (10%) (per mL): $1.83

Tablets (Cipro Oral)

250 mg (per each): $5.88

500 mg (per each): $6.88

Tablets (Ciprofloxacin HCl Oral)

100 mg (per each): $15.22

250 mg (per each): $0.24 - $4.59

500 mg (per each): $0.22 - $5.59

750 mg (per each): $5.17 - $5.65

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA

Pharmacodynamics/Kinetics

Absorption: Oral: Well-absorbed; 500 mg orally every 12 hours produces an equivalent AUC to that produced by 400 mg IV over 60 minutes every 12 hours

Distribution: Vd: 2.1 to 2.7 L/kg; tissue concentrations often exceed serum concentrations especially in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic tissue; CSF concentrations: 10% of serum concentrations (noninflamed meninges), 14% to 37% (inflamed meninges)

Protein binding: 20% to 40%

Metabolism: Partially hepatic; forms 4 metabolites (limited activity)

Bioavailability: Oral: 50% to 85%; younger CF patients have a lower bioavailability of 68% vs CF patients >13 years of age with bioavailability of 95%

Half-life elimination: Children: 4 to 5 hours; Adults: Normal renal function: 4 to 6 hours

Time to peak: Oral:

Immediate release tablet: 0.5 to 2 hours

Extended release tablet: Cipro XR: 1 to 2.5 hours

Excretion: Urine (35% to 70% as unchanged drug); feces (15% to 35%; <1% as unchanged drug)

Clearance: After IV: CF children: 0.84 L/hour/kg; Adults: 0.5 to 0.6 L/hour/kg

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: The half-life is prolonged.

Geriatric: Cmax increased 16% to 40%, AUC increased approximately 20% to 30%, and half-life increased approximately 20%.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Desensitization Protocols
• Dosing Considerations for the Critically Ill Patient With Morbid Obesity
• Oral Medications That Should Not Be Crushed or Altered
• Relative Infant Dose

Index Terms

Ciprofloxacin HCl; Ciprofloxacin Hydrochloride; Proquin XR

FDA Approval Date

October 22, 1987

References

Aggarwal P, Dutta S, Garg SK, et al, "Multiple Dose Pharmacokinetics of Ciprofloxacin in Preterm Babies," Indian Pediatr, 2004, 41(10):1001-7.[PubMed 15523125]

Agha R, Goldberg MB. Shigella infection: Treatment and prevention in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 15, 2019.

Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.[PubMed 27060684]

Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 66.

Baddour LM, Harper M. Animal bites (dogs, cats, and other animals): evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019a.

Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019b.

Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in Circulation. 2015;132(17):e215]. Circulation. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.[PubMed 26373316]

Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation. 2015;132(15):1487-1515.[PubMed 26373317]

Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143(2):75-78.[PubMed 19181435 ]

Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019.

Beckwith MC, Feddema SS, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm. 2004;39(3):225-237.

Berbari E, Baddour LM. Prosthetic joint infection: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 5, 2019.

Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.[PubMed 26229122]

Berdal JE, Skråmm I, Mowinckel P, et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin Microbiol Infect. 2005;11(10):843-845. doi: 10.1111/j.1469-0691.2005.01230.x.[PubMed 16153261]

Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital characteristics and geographic region? Antimicrob Agents Chemother. 2016;60(5):3170-3173. doi: 10.1128/AAC.02505-15.[PubMed 26926640]

Bitton A, Fichera A. Perianal Crohn’s disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019.

Bossi P, Tegnell A, Baka A, et al; Taskforce on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. BICHAT guidelines for the clinical management of tularemia and bioterrorism-related tularemia. Euro Surveill. 2004;9(12):E9-E10.[PubMed 15677845]

Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011a;53(7):e25-e76.[PubMed 21880587]

Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011b;128(4):e1034-e1045.[PubMed 21949152]

Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014;133(5):e1411-e1436.[PubMed 24777226]

Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society of Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.[PubMed 23327981]

Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am. 2005;19(4):765-786.[PubMed 16297731]

Campoli-Richards DM, Monk JP, Price A, et al, "Ciprofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use," Drugs, 1988, 35(4):373-447.[PubMed 3292209]

Centers for Disease Control and Prevention. Plague. Resources for clinicians. http://www.cdc.gov/plague/healthcare/clinicians.html#treatment. Updated October 5, 2015a. Accessed June 9, 2016.

Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1-28. Available at http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf[PubMed 15917737]

Centers for Disease Control and Prevention. Recommendations for the use of antibiotics for the treatment of cholera: summary recommendations. 2015. https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html. Updated January 20, 2015.

Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea. Updated June 13, 2017. Accessed September 6, 2017.

Centers for Disease Control and Prevention, “Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,” MMWR Recomm Rep, 2007, 56(14):332-6.[PubMed 17431378]

Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966.[PubMed 24935270]

Chung AM, Reed MD, and Blumer JL, “Antibiotics and Breast-Feeding: A Critical Review of the Literature,” Paediatr Drugs, 2002, 4(12):817-37.[PubMed 12431134]

Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2019.

Cipro, Cipro Oral Suspension (ciprofloxacin) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; January 2020.

Cipro IV (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2019.

Cipro XL (ciprofloxacin) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2020.

Cipro XR (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2019.

Ciprofloxacin injection [prescribing information]. North Brunswick, NJ: Claris Lifesciences; May 2017.

Ciprofloxacin injection [prescribing information]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; September 2018.

Ciprofloxacin injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; January 2019.

Ciprofloxacin injection, solution [prescribing information]. Lake Forest, IL: Hospira Inc; May 2019.

Ciprofloxacin tablet [prescribing information]. Saddle Brook, NJ: Rising Pharmaceuticals Inc; February 2019.

Coker TJ, Dierfeldt DM. Acute bacterial prostatitis: Diagnosis and management. Am Fam Physician. 2016;93(2):114-120.[PubMed 26926407]

Committee on Infectious Diseases, “The Use of Systemic Fluoroquinolones,” Pediatrics, 2006, 118(3):1287-92.[PubMed 16951028]

Cover DL, Mueller BA. Ciprofloxacin penetration into human breast milk: a case report. DICP. 1990;24(7-8):703-704.[PubMed 2375140]

Davies SP, Azadian BS, Kox WJ, et al, “Pharmacokinetics of Ciprofloxacin and Vancomycin in Patients With Acute Renal Failure Treated by Continuous Haemodialysis,” Nephrol Dial Transplant, 1992, 7(8):848-54.[PubMed 1325620]

de la Cabada Bauche J and DuPont HL. “New Developments in Traveler’s Diarrhea,” Gastroenterol Hepatol, 2011, 7(2):88-95.[PubMed 21475415]

Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.[PubMed 11386933]

File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 12, 2019.

Food and Drug Administration (FDA), “CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women.” Available at http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm

Food and Drug Administration. FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm. Published May 12, 2016

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.[PubMed 21258094]

Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med. 1999;341(5):305-311. doi:10.1056/NEJM199907293410501.[PubMed 10423464]

Friedrich LV and Dougherty R, “Fatal Hypoglycemia Associated With Levofloxacin,” Pharmacotherapy, 2004, 24(12):1807-12.[PubMed 15585448]

Gamboa F, Rivera JM, Gomez Mateos JM, et al, “Ciprofloxacin-Induced Henoch-Schönlein Purpura,” Ann Pharmacother, 1995, 29(1):84.

Gardner DK, Gabbe SG, and Harter C, "Simultaneous Concentrations of Ciprofloxacin in Breast Milk and in Serum in Mother and Breast-Fed Infant," Clin Pharm, 1992, 11(4):352-4.[PubMed 1563233]

Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women. Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida. Am J Med. 1989;87(5A):49S-51S.[PubMed 2589353 ]

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Published 2020. Accessed February 26, 2020.

Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” J Antimicrob Chemother, 2012, 67(2):269-89.[PubMed 22086858]

Guay DRP, Awni WM, Peterson PK, et al, “Single and Multiple Dose Pharmacokinetics of Oral Ciprofloxacin in Elderly Patients,” Int J Clin Pharmacol Ther Toxicol, 1988, 26(6):279-84.[PubMed 3410603]

Guerrant RL, Van Gilder T, Steiner TS, et al; Infectious Diseases Society of America. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32(3):331-351.[PubMed 11170940]

Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120.[PubMed 21292654]

Harmon T, Burkhart G, and Applebaum H, "Perforated Pseudomembranous Colitis in the Breast-Fed Infant," J Pediatr Surg, 1992, 27(6):744-6.[PubMed 1501036]

Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. doi: 10.7326/M15-1840.[PubMed 26785402]

Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2013. Available at http://aidsinfo.nih.gov/guidelines.

Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996;40(1):6-10.[PubMed 8787869]

Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577.[PubMed 19397464]

Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).[PubMed 24447897]

Hohmann EL. Nontyphoidal Salmonella: Gastrointestinal infection and carriage. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA. 1991;265(12):1563-1565.[PubMed 1999905]

Hooton TM, Gupta K. Acute simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019a.

Hooton TM, Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019b.

Hughes WT, Armstrong D, Bodey GP, et al, “2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer,” Clin Infect Dis, 2002, 15;34(6):730-51.[PubMed 11850858]

Inglesby TV, Dennis DT, Henderson DA, et al; Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. JAMA. 2000;283(17):2281-2290.[PubMed 10807389]

Inglesby TV, Henderson DA, Bartlett JG, et al, "Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense," JAMA, 1999, 281(18):1735-45.[PubMed 10328075]

Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]

Kaguelidou F, Turner MA, Choonara I, et al, "Ciprofloxacin Use in Neonates: A Systematic Review of the Literature," Pediatr Infect Dis J, 2011, 30(2):e29-37.[PubMed 21048525]

Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. Clin Infect Dis. doi:10.1093/cid/ciw353.[PubMed 27418577]

Kapila K, Chysky V, Hullman R, et al, “Worldwide Clinical Experience on Safety of Ciprofloxacin in Children on Compassionate Use Basis,” Proceedings of Third International Symposium on New Quinolones, Vancouver, Canada, 1990, 9.

Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. Can Fam Physician. 2015;61(4):343-344.[PubMed 26052598]

Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1999;341(5):312-318.[PubMed 10423465]

Kern WV, Marchetti O, Drgona L, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(9):1149-1156. doi:10.1200/JCO.2012.45.8109.[PubMed 23358983]

Khaliq Y and Zhanel GG, “Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,” Clin Infect Dis, 2003, 36(11):1404-10.[PubMed 12766835]

Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet. 1996;348(9023):296-300.[PubMed 8709688]

Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics (AAP). Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.

Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Krcméry V Jr, Filka J, Uher J, et al, "Ciprofloxacin in Treatment of Nosocomial Meningitis in Neonates and in Infants: Report of 12 Cases and Review," Diagn Microbiol Infect Dis, 1999, 35(1):75-80.[PubMed 10529884]

Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72(12):1369-1378. doi: 10.1016/j.jacc.2018.06.067.[PubMed 30213330]

Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27. Erratum in: Am J Gastroenterol. 2018;113(7):1101.[PubMed 29610508]

Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-e173.[PubMed 22619242]

Loebstein R, Addis A, Ho E, et al, “Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,” Antimicrob Agents Chemother, 1998, 42(6):1336-9.[PubMed 9624471]

Lomaestro BM and Bailie GR, “Quinolone-Cation Interactions: A Review,” DICP, 1991, 25(11):1249-58.[PubMed 1763542]

Ludlam H, Wreghitt TG, Thornton S, et al, "Q Fever in Pregnancy," J Infect, 34(1):75-8.[PubMed 9120330]

Mackay AD and Mehta A, “Autoimmune Haemolytic Anemia Associated With Ciprofloxacin,” Clin Lab Haematol, 1995, 17(1):97-8.[PubMed 7621639]

Malone RS, Fish DN, Abraham E, et al, “Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,” Antimicrob Agents Chemother, 2001, 45(10):2949-54.[PubMed 11557500]

Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. doi: 10.1089/sur.2016.261.[PubMed 28085573]

Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2).[PubMed 24457117 ]

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.[PubMed 31573350]

Meyrier A, Fekete T. Acute bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 5, 2019a.

Meyrier A, Fekete T. Chronic bacterial prostatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 15, 2019b.

Mohr JF, McKinnon PS, Peymann PJ, et al, “A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,” Pharmacotherapy, 2005, 25(10):1303-9.[PubMed 16185173]

Mullen CA, “Ciprofloxacin in Treatment of Fever and Neutropenia in Pediatric Cancer Patients,” Pediatr Infect Dis J, 2003, 22(12):1138-42.[PubMed 14688588]

Nilsson-Ehle I and Ljungberg B, “Quinolone Disposition in the Elderly: Practical Implications,” Drugs Aging, 1991, 1(4):279-88.[PubMed 1794020]

Nix DE, Cumbo TJ, Kuritzky P, DeVito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. Am J Med. 1987;82(4A):146-153.[PubMed 3555029]

Nouira S, Marghli S, Besbes L, et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis. 2010;51(2):143-149. doi: 10.1086/653527.[PubMed 20536364]

Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25.[PubMed 23223583]

Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019.

Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. Antimicrob Agents Chemother. 2014;58(8):4392-4398.[PubMed 24841264 ]

Paul J and Brown NM, “Tinnitus and Ciprofloxacin,” BMJ, 1995, 311(6999):232.

Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019.

Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989;86(6 Pt 2):801-808.[PubMed 2658581]

Rfidah EI, Findlay CA, and Beattie TJ, “Reversible Encephalopathy After Intravenous Ciprofloxacin Therapy,” Pediatr Nephrol, 1995, 9(2):250-1.[PubMed 7794728]

Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med. 2017;24(suppl 1):S57-S74.[PubMed 28521004]

Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602-622. doi: 10.1038/ajg.2016.126.[PubMed 27068718]

Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology. 1995;22(4, pt 1):1171-1174.[PubMed 7557868 ]

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis executive summary. Otolaryngol Head Neck Surg. 2015;152(4):598-609. doi: 10.1177/0194599815574247.[PubMed 25833927]

Rubio TT, Miles MV, Lettieri JT, et al, “Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation,” Pediatr Infect Dis J, 1997, 16:112-7.[PubMed 9002120]

Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases; 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 12, 2015.

Runyon BA. Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 4, 2019.

Ryan ET, Andrew J. Treatment and prevention of enteric (typhoid and paratyphoid) fever. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354(23):2452-2462.[PubMed 16760445]

Schaad UB, abdus Salam M, Aujard Y, et al, “Use of Fluoroquinolones in Pediatrics: Consensus Report of an International Society of Chemotherapy Commission,” Pediatr Infect Dis J, 1995, 14(1):1-9.[PubMed 7715981]

Sedlak T, Shufelt C, Iribarren C, et al, "Oral Contraceptive Use and the ECG: Evidence of an Adverse QT Effect on Corrected QT Interval," Ann Noninvasive Electrocardiol, 2013, 18(4):389-98.[PubMed 23879279]

Sethi S, Murphy TF. Management of infection in exacerbations of chronic obstructive pulmonary disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80.[PubMed 29053792]

Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2010;50(12):1695]. Clin Infect Dis. 2010;50(2):133-164.[PubMed 20034345]

Spach DH, Kaplan SL. Treatment of cat scratch disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2015;60(9):1448]. Clin Infect Dis. 2014;59(2):e10-e52.[PubMed 24973422]

Stockmann C, Sherwin CM, Zobell JT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol. 2013;48(3):211-220.[PubMed 22949224 ]

Szarfman A, Chen M, and Blum MD, “More on Fluoroquinolone Antibiotics and Tendon Rupture,” N Engl J Med, 1995, 332(3):193.

Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. Perit Dial Int. 2017;37(2):141-154.[PubMed 28360365]

Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes [published online November 18, 2019]. Am J Clin Dermatol. 2019;10.1007/s40257-019-00485-z.[PubMed 31741184]

Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-1453. doi:10.1200/JCO.2017.77.6211.[PubMed 29461916]

Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol. 2008;48(5):774-779.[PubMed 18316137 ]

Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-1238.[PubMed 19747629]

Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166.[PubMed 16163635]

Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284.[PubMed 15494903]

Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34-e65.[PubMed 28203777]

Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-39.[PubMed 12685882]

Umut S, Tutluoglu B, Aydin Tosun G, et al. Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group. J Chemother. 1999;11(3):211-214. doi: 10.1179/joc.1999.11.3.211.[PubMed 10435684]

US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated September 24, 2015. Accessed September 25, 2015.

van den Oever HL, Versteegh FG, Thewessen EA, et al, "Ciprofloxacin in Preterm Neonates: Case Report and Review of the Literature," Eur J Pediatr, 1998, 157(10):843-5.[PubMed 9809826]

Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;32(suppl 2):S32-S86.[PubMed 22851742]

Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 29, 2019.

Wingard RJ. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015;64(33):924]. MMWR Recomm Rep. 2015;64(RR-03):1-137.[PubMed 26042815]

World Health Organization (WHO). Acute diarrhea in adults and children: a global perspective. 2012. Available at http://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea/acute-diarrhea-english

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

World Health Organization (WHO), “Guidelines for the Control of Shigellosis, Including Epidemics Due to Shigella dysenteriae type 1”, 2005. Available at http://whqlibdoc.who.int/publications/2005/9241592330.pdf

World Health Organization (WHO). WHO guidelines on tularaemia. 2007. Available at http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf

Yoon BI, Han DS, Ha US, et al. Clinical courses following acute bacterial prostatitis. Prostate Int. 2013;1(2):89-93. doi: 10.12954/PI.12013.[PubMed 24223408]

Zacher JL and Givone DM, “False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,” Ann Pharmacother, 2004, 38:1525-28.[PubMed 15252190]

Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group, “Multicenter, Randomized, Double Blind Clinical Trial of Short Course Versus Standard Course Oral Ciprofloxacin for Shigella dysenteriae Type 1 Dysentery in Children,” Pediatr Infect Dis J, 2002, 21(12):1136-41.[PubMed 12488664]

Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537-1541.[PubMed 9605897]

Brand Names: International

AC Ear Drops (IN); Acipro (PH); Aciren (KR); Adiflox (IN); Alcon Cilox (CO, ID); Antox (CR, DO, GT, HN, NI, PA, SV); Apoflox (MX); Aprocin (HK); Asflox (ET); Bacquinor (ID); Bactiflox (BF, BJ, CI, EG, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW); Baflox (CO); Baquinor (ID); Baycip (CL, ES); Bearcin (KR); Bernoflox (ID); C-Flox (AU, UY); Cefaxin (KR); Ceflox (IN); Cetraxal (CR, DO, ES, GT, HN, NI, PA, SV); Ciclodin (PH); Cifex (PH); Cifloc (ZA); Ciflodal (PH); Ciflomed (PH); Cifloptic (PE); Ciflox (AE, FR, HR, KW, QA, VE); Cifloxager (IE); Cifloxin (HK, PH); Cifox (IE); Cifran (AU, BF, BJ, CI, CN, ET, GH, GM, GN, IN, KE, LK, LR, LV, MA, ML, MR, MU, MW, NE, NG, RO, SC, SD, SL, SN, TN, TZ, UA, UG, VN, ZM, ZW); Cilobact (CO); Cilox (NO); Cimoxin (PE); Cinaflox (PE); Cinolone (MY); Cipflox (NZ); Ciploc (PK); Ciplox (BF, BJ, CI, ET, GH, GM, GN, HK, IE, KE, LR, LV, MA, ML, MR, MU, MW, NE, NG, SC, SD, SK, SL, SN, TN, TZ, UG, ZA, ZM, ZW); Ciplus (KR); Cipquin (MY); Ciprecu (EC); Ciprinol (BG, EE, LV, RO, SI); Cipro (AR, BR, CO, JO, PY); Cipro A (BD); Cipro XR (BB, BM); Cipro-Denk (TZ); Ciprobac (MX); Ciprobay (AE, BG, BH, CY, CZ, EG, IQ, IR, JO, KR, KW, LB, LY, MY, OM, PH, PL, QA, SA, SI, SY, TH, UA, VN, YE, ZA, ZW); Ciprobay Uro (DE); Ciprobeta (DE); Ciprobid (AE, BF, BJ, CI, CY, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW); Ciprobiotic (GT, HN, ID, NI); Ciprocan (KR); Ciprocep (TH); Ciprocin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Ciprodac (ZW); Ciprodar (AE, CY, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE); Ciprodex (IL); Ciproflox (CY, PE, SA); Ciproglen (MY); Ciprol (AU); Ciprolak (PE); Ciprolet (SG); Ciprolin (PE); Ciprolon (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Cipromed (PE); Cipromycin (GR); Cipropharm (AE, CY, ET, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Ciprophil (PH); Ciproquin (QA); Ciprotal (PH); Ciprouro SR (KR); Ciproval (CL); Ciprovar (ZW); Ciprovita (PH); Ciprox (AE, CY, IQ, IR, JO, KW, LB, LY, MY, OM, SA, SY, YE); Ciproxan (JP); Ciproxin (AT, AU, CH, DK, FI, GB, GR, HK, ID, IT, KR, MT, NO, NZ, SE, TR, TW, ZW); Ciproxin XR (ID); Ciproxina (BB, BM, BS, BZ, CR, CU, DO, EC, GT, HN, JM, MX, NI, NL, PA, PR, PT, SR, SV, TT); Ciproxine (BE, LU); Ciproxyl (HK, TH); Cipzy (LK); Ciriax (PE); Cirok (PH, SG); Ciroxin (TW); Citopcin (KR); Cixa (TW); Cobay (TH); Cobay-500 (PH); Cosflox (IN); Cycin (KR, SG); Cyflox (TH); Cyplox (HK); Cypral (VE); Cypro (KR); Dibactil (PY); Eni (CR, DO, GT, HN, NI, PA, SV); Enoxin (SG, TH); Eprocin (KR); Estecina (ES); Fexin (PH); Flaprox (UA); Floroxin (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Floxabid (BD); Floxager (MX); Floxine (ET); Floxsid (ID); Giroflox (IL); Glocip (VN); Glojaya (ID); Hexiquin (ID); Hiflox (BD); Hippro (TH); Hippro Forte (TH); Ifloxin (PH); Interflox (ID); Iprolan (PH); Iprubac (PH); Jayacin (ID); Karmaflox (EG); Ladinin (ET); Lofucin (KR); Loxan (CO); Maxpro (PH); Medcoflox (ID); Novaflox (SG); Novidat (AR); Oftacilox (PT); Optal-Pro (TH); Orlin (AE); Orpic (PH); Otosec (CO, PE); Picaroxin (VN); Procip (NZ, ZW); Proflox (EC, TH); Profloxin (IE); Proxacin (BD, BR); Pycip (MY); Qilaflox (ID); Qinosyn (PH); Quilox (PH); Quinobiotic (ID, PE); Quinocip (LK); Quinos (KR); Quintor (BH, ET); Qupron (KR); Rancif (EG); Sepcen (MT); Serviflox (MY, SG); Sifloks (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Siflox (ID); Sophixin Ofteno (CR, DO, GT, HN, NI, PA, SV, VE); Superocin (TW); Supraflox (ET); Tequinol (ID); Topistin (SG); Truoxin (IE); Tyflox (ZW); Unex (EC); Uniflox (FR); Uroxin (HK, SG); Vexcipro (PH); Viflox (ID); Viprolox (SG); Vistaflox (PH); Xenoflox (PH); Zindolin (TR); Zumaflox (ID)

Last Updated 3/20/20